Advertisement

Topics

MEI Pharma, BeiGene ink clinical collaboration to evaluate ME─401 in combo with zanubrutinib to treat B─cell malignancies

17:25 EDT 12 Oct 2018 | PharmaBiz

MEI Pharma, Inc., a late─stage pharmaceutical company focused on advancing new therapies for cancer, and BeiGene, Ltd., a commercial─stage biopharmaceutical company, announced a clinical collaboration to

Original Article: MEI Pharma, BeiGene ink clinical collaboration to evaluate ME─401 in combo with zanubrutinib to treat B─cell malignancies

NEXT ARTICLE

More From BioPortfolio on "MEI Pharma, BeiGene ink clinical collaboration to evaluate ME─401 in combo with zanubrutinib to treat B─cell malignancies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...